Testing a new drug combination for advanced kidney cancer

This trial is testing whether combining pazopanib with a new drug called abexinostat works better than pazopanib alone for treating advanced kidney cancer that cannot be surgically removed or has spread to other parts of the body. About half of participants will receive the medication combination, while the other half will receive pazopanib with a placebo (a pill with no active drug). If the cancer progresses in the placebo group, those patients will have the option to switch to the combination therapy.

Kidney cancer that has spread or cannot be operated on is very difficult to treat, and current therapies don't work well enough for all patients. Researchers believe that combining this medication with abexinostat might help the treatment work better by attacking the cancer in multiple ways.